# A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

> **NCT00654420** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 95 (actual)

## Conditions studied

- Carcinoma, Non-small-cell Lung

## Interventions

- **DRUG:** Dalotuzumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00654420
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-19
- **Primary completion:** 2009-11-25
- **Final completion:** 2012-02-13
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654420, "A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00654420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*